Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Bristol Meyers Squibb Company

Viiv Healthcare UK Limited

Stanley V D'Andrea

Zhizhen Barbara Zheng

Paul Michael Scola

Joanne J Bronson

Yasutsugu Ueda

B Narasimhulu Naidu

John D Matiskella

Peter F Misco

John A Wichtowski

Shelley E Hoeft

David R Langley

Thomas W Hudyma

Manoj Patel

Muzammil M Mansuri

Choung U Kim

Andrew Charles Good

Jeffrey Allen Campbell

Kevin M Peese

Alan Xiangdong Wang

Zhongyu Wang

Dane M Springer

Fiona McPhee

Raymond F Miller

Barbara Zhizhen Zheng

Nicholas A Meanwell

John F Kadow

Michael A Walker

Timothy P Connolly

David J Carini

Oak K Kim

Barry L Johnson

Bing Y Luh

Annapurna Pendri

Kenneth M Boy

Qian Zhao

Samuel Gerritz

Yong Tu

Anita H Lewin

Wenying Li

F Ivy Carroll

Guo Li

Weixu Zhai

Jianqing Li

Roman Z Sterzycki

Amy Ripka

Katharine M Greene

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Inhibitors of human immunodeficiency virus replication

The present invention provides (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1 -methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl) carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compound for the treatment of hepatitis C

Macrocyclic peptides are disclosed having the general formula:  wherein R, R', R, R, R&#x2032;, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of hepatitis C virus

Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Macrocyclic peptides are disclosed having the general formula: 

Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I:  wherein Rto R, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Substituted cycloalkyl P1' hepatitis C virus inhibitors

Provided by the present invention are cephem derivatives represented by the general formula

Bis quaternary MRSA cephem derivatives

Growing community of inventors

Middletown, CT, United States of America

Stanley V D'Andrea